Becton, Dickinson and Company $BDX Position Cut by Curi RMB Capital LLC

Curi RMB Capital LLC trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 36.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,506 shares of the medical instruments supplier’s stock after selling 26,496 shares during the quarter. Curi RMB Capital LLC’s holdings in Becton, Dickinson and Company were worth $10,653,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BDX. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after purchasing an additional 1,259,750 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Becton, Dickinson and Company by 3.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock valued at $2,880,510,000 after purchasing an additional 448,644 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after purchasing an additional 667,957 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Becton, Dickinson and Company by 7.6% during the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock valued at $1,012,649,000 after purchasing an additional 312,124 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Becton, Dickinson and Company by 1.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier’s stock valued at $707,872,000 after purchasing an additional 37,733 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

BDX opened at $191.31 on Friday. The stock has a fifty day moving average of $184.65 and a 200-day moving average of $193.31. The firm has a market capitalization of $54.83 billion, a P/E ratio of 34.41, a PEG ratio of 1.42 and a beta of 0.27. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Claire Fraser sold 863 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the sale, the director owned 23,143 shares of the company’s stock, valued at $4,450,398.90. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on BDX shares. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Piper Sandler reiterated a “neutral” rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Barclays cut their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research report on Tuesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.